Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, HSBC Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target boosted by analysts at HSBC from $110.00 to $133.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. HSBC’s target price indicates a potential upside of 7.95% from the stock’s previous close.

GILD has been the topic of a number of other reports. Mizuho increased their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. UBS Group raised shares of Gilead Sciences to a “hold” rating in a research note on Thursday, December 4th. Finally, The Goldman Sachs Group raised their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $130.96.

Gilead Sciences Trading Up 1.5%

NASDAQ GILD opened at $123.21 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock’s 50-day simple moving average is $121.74 and its two-hundred day simple moving average is $115.62. Gilead Sciences has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a market capitalization of $152.86 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the sale, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 135,757 shares of company stock worth $16,616,127 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sivik Global Healthcare LLC lifted its holdings in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after purchasing an additional 10,000 shares in the last quarter. One Wealth Advisors LLC raised its position in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares during the last quarter. Invesco Ltd. raised its position in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Ariel Investments LLC lifted its stake in Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares during the period. Finally, Simplify Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 148.6% during the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.